PolyMedix, Inc. (OTC:PYMX) has announced the completion of the first two segments of a Phase 1B clinical safety study for its antibiotic drug candidate PMX-30063. The study’s data shows the administration of multiple doses of PMX-30063 at varying levels are safe and well tolerated. The doses and blood levels suggest a potential therapy benefit from the drug.
MicroCap Insider is a web-based financial portal.
Sign Up for our Free Stock Newsletter
MicroCap Insider publishes a free penny stock newsletter providing stock alerts on companies positioned to deliver high-yield gains to investors.
PolyMedix, Inc. is focused on the treatment of life threatening, serious, infectious diseases and acute cardiovascular disorders. The biotechnology uses synthetic molecule compounds to mimic the activity of large natural protein molecules. The molecule compounds are known as biomimetics.
Sign Up for FREE. Investors interested in receiving small cap stock alerts through the penny stock newsletter published by MicroCap Insider can sign up for free by visiting our website.
About Us
MicroCap Insider is a leading penny stock web site with extensive experience in the OTC market, providing top stock picks, investing tips and exclusive research on small cap stocks on the verge of producing large financial gains.
Please click here to read the full disclaimer.
